Literature DB >> 22135129

Clopidogrel (plavix).

J Comin1, D Kallmes.   

Abstract

Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22135129      PMCID： PMC7964406          DOI： 10.3174/ajnr.A2913

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


  14 in total

1.  ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Authors:  Neena S Abraham; Mark A Hlatky; Elliott M Antman; Deepak L Bhatt; David J Bjorkman; Craig B Clark; Curt D Furberg; David A Johnson; Charles J Kahi; Loren Laine; Kenneth W Mahaffey; Eamonn M Quigley; James Scheiman; Laurence S Sperling; Gordon F Tomaselli
Journal:  J Am Coll Cardiol       Date:  2010-12-07       Impact factor: 24.094

2.  A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.

Authors:  Gilles Montalescot; Georges Sideris; Catherine Meuleman; Claire Bal-dit-Sollier; Nicolas Lellouche; Ph Gabriel Steg; Michel Slama; Olivier Milleron; Jean-Philippe Collet; Patrick Henry; Farzin Beygui; Ludovic Drouet
Journal:  J Am Coll Cardiol       Date:  2006-08-17       Impact factor: 24.094

3.  Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.

Authors:  Ralph L Sacco; Robert Adams; Greg Albers; Mark J Alberts; Oscar Benavente; Karen Furie; Larry B Goldstein; Philip Gorelick; Jonathan Halperin; Robert Harbaugh; S Claiborne Johnston; Irene Katzan; Margaret Kelly-Hayes; Edgar J Kenton; Michael Marks; Lee H Schwamm; Thomas Tomsick
Journal:  Stroke       Date:  2006-02       Impact factor: 7.914

4.  2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee.

Authors:  Spencer B King; Sidney C Smith; John W Hirshfeld; Alice K Jacobs; Douglass A Morrison; David O Williams; Ted E Feldman; Morton J Kern; William W O'Neill; Hartzell V Schaff; Patrick L Whitlow; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  Circulation       Date:  2007-12-13       Impact factor: 29.690

5.  Thrombotic thrombocytopenic purpura associated with clopidogrel.

Authors:  C L Bennett; J M Connors; J M Carwile; J L Moake; W R Bell; S R Tarantolo; L J McCarthy; R Sarode; A J Hatfield; M D Feldman; C J Davidson; H M Tsai
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

6.  Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.

Authors:  L A Harker; J P Boissel; A J Pilgrim; M Gent
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

7.  Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.

Authors:  Jersey Chen; Deepak L Bhatt; Elizabeth Schneider Dunn; Chunxue Shi; J Jaime Caro; Elizabeth M Mahoney; Sylvie Gabriel; Joseph D Jackson; Eric J Topol; David J Cohen
Journal:  Value Health       Date:  2009-03-11       Impact factor: 5.725

8.  Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.

Authors:  Dirk Sibbing; Tanja Morath; Julia Stegherr; Siegmund Braun; Wolfgang Vogt; Martin Hadamitzky; Albert Schömig; Adnan Kastrati; Nicolas von Beckerath
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

9.  Genetic determinants of response to clopidogrel and cardiovascular events.

Authors:  Tabassome Simon; Céline Verstuyft; Murielle Mary-Krause; Lina Quteineh; Elodie Drouet; Nicolas Méneveau; P Gabriel Steg; Jean Ferrières; Nicolas Danchin; Laurent Becquemont
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

Review 10.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

Authors:  Dominick J Angiolillo; Antonio Fernandez-Ortiz; Esther Bernardo; Fernando Alfonso; Carlos Macaya; Theodore A Bass; Marco A Costa
Journal:  J Am Coll Cardiol       Date:  2007-03-26       Impact factor: 24.094
View more
  4 in total

1.  Delayed ipsilateral parenchymal hemorrhage following flow diversion for the treatment of anterior circulation aneurysms.

Authors:  J P Cruz; M Chow; C O'Kelly; B Marotta; J Spears; W Montanera; D Fiorella; T Marotta
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-08       Impact factor: 3.825

2.  Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase.

Authors:  Gregory R Tintinger; Annette J Theron; Helen C Steel; Moloko C Cholo; Jan G Nel; Charles Feldman; Ronald Anderson
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

3.  Change of Platelet Reactivity to Antiplatelet Therapy after Stenting Procedure for Cerebral Artery Stenosis: VerifyNow Antiplatelet Assay before and after Stenting.

Authors:  Deok Hee Lee; Ho Sung Kim; Sun Mi Kim; Sun-Uck Kwon; Dae Chul Suh
Journal:  Neurointervention       Date:  2012-02-29

Review 4.  An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease.

Authors:  Nicholas P Iskandar; Akshay J Reddy; Allen Dang; Muhammad S Ghauri; Mildred Min; Mark Bachir; Alex Bachir; Himanshu Wagh; Nathaniel Tak; Hetal Brahmbhatt
Journal:  Cureus       Date:  2022-08-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.